NCT02127814View on ClinicalTrials.gov

Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile

NACompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

August 31, 2014

Study Completion Date

December 31, 2017

Conditions
Antibiotic-associated DiarrheaClostridium Difficile
Interventions
DIETARY_SUPPLEMENT

Lactobacillus reuteri

One chewable tablet of 1E8 CFU L. reuteri, once per day

Trial Locations (1)

44106

University Hospitals Case Medical Center, Cleveland

Sponsors

Collaborators (1)

BioGaia AB
All Listed Sponsors
collaborator

BioGaia AB

INDUSTRY

lead

Case Western Reserve University

OTHER

NCT02127814 - Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile | Biotech Hunter | Biotech Hunter